Form 4: Ultragenyx Executive Receives Equity Grant

EVP & Chief Commercial Officer Erik Harris was granted 28,895 restricted stock units and 49,960 stock options by Ultragenyx Pharmaceutical.

Summary

• Erik Harris, EVP & Chief Commercial Officer, received an equity grant on April 16, 2026.
• The grant includes 28,895 Restricted Stock Units (RSUs) vesting over four years.
• The grant includes 49,960 stock options with an exercise price of $24.52, expiring in 2036.
• Following these transactions, the reporting person holds 118,410 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership personnel in the commercial division.

Negatives

• Potential for future shareholder dilution upon the vesting and exercise of these equity awards.

Risks

• Market volatility affecting the value of the granted options.
• Vesting conditions tied to continued employment and performance metrics.

Future Outlook

The equity grants are subject to standard vesting schedules, with RSUs vesting annually over four years and options beginning to vest after one year, followed by monthly vesting.

Management Comments

• The grants are issued under the Company's 2023 Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice for aligning management incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a four-year vesting schedule for RSUs is consistent with standard corporate governance practices in the biopharmaceutical industry.
• The inclusion of both RSUs and stock options is a common compensation structure for executive retention in mid-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options and vesting of RSUs.

Next Steps

• Vesting of 1/4th of RSUs on the first anniversary of the grant date.
• Vesting of 1/4th of stock options on the first anniversary of the grant date.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Executive Compensation